Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Yew, Nelson S ^a   Zhao, Hongmei ^a   Hong, Eun Gyoung ^b,c   Wu, I Huan ^a   Przybylska, Malgorzata ^a   Siegel, Craig ^a   Shayman, James A ^d   Arbeeny, Cynthia M ^a   Kim, Jason K ^b,e   Jiang, Canwen ^a   Cheng, Seng H ^a  

^a GENZYME CORPORATION   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hallym University College of Medicine   (South Korea)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; ELIGLUSTAT TARTRATE; GENZ 112638; GLYCOSPHINGOLIPID; HEMOGLOBIN A1C; INSULIN; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GENZ-112638; GLUCOSE; GLUCOSYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; PYRROLIDINE DERIVATIVE; SPHINGOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FATTY LIVER; GAUCHER DISEASE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE ACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OBESITY; TREATMENT DURATION; ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; DIET; DRUG ANTAGONISM; DRUG EFFECT; EATING; ENZYMOLOGY; HYPERINSULINISM; LIVER; METABOLISM; PATHOPHYSIOLOGY;

MUS;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DIET; EATING; ENZYME INHIBITORS; FATTY LIVER; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSYLTRANSFERASES; HEMOGLOBIN A, GLYCOSYLATED; HYPERINSULINISM; INSULIN; LIVER; MALE; MICE; OBESITY; PYRROLIDINES; SPHINGOLIPIDS;

EID: 77955300117     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011239     Document Type: Article

References (28)

1. Qatanani M, Lazar MA (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21: 1443-1455.
2. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L (2010) Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 6: 71-82.
3. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152.
4. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
5. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838.
6. Buse JB, Polonsky KS, Burant CF (2003) Type 2 Diabetes Mellitus. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. Philadelphia: Elsevier Science (USA). pp 1427-1483.
7. Home PD, Pacini G (2008) Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes Metab 10: 699-718.
8. Girard J (2006) Insulin's effect on the liver: ''direct or indirect?'' continues to be the question. J Clin Invest 116: 302-304.
9. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, et al. (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56: 1210-1218.
10. Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, et al. (2009) Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50: 85-93.
11. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, et al. (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56: 1341-1349.
12. Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, et al. (2002) Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 277: 3085-3092.
13. Langeveld M, Aerts JM (2009) Glycosphingolipids and insulin resistance. Prog Lipid Res 48: 196-205.
14. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267.
15. Turinsky J, O'Sullivan DM, Bayly BP (1990) 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 265: 16880-16885.
16. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, et al. (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5: 167-179.
17. Summers SA (2006) Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45: 42-72.
18. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, et al. (2009) Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 297: E211-224.
19. Glaros EN, Kim WS, Wu BJ, Suarna C, Quinn CM, et al. (2007) Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 73: 1340-1346.
20. Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, et al. (2007) Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci U S A 104: 13678-13683.
21. Inokuchi J (2006) Insulin resistance as a membrane microdomain disorder. Biol Pharm Bull 29: 1532-1537.
22. Kasahara K, Sanai Y (2000) Functional roles of glycosphingolipids in signal transduction via lipid rafts. Glycoconj J 17: 153-162.
23. Bijl N, Sokolovic M, Vrins C, Langeveld M, Moerland PD, et al. (2009) Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology.
24. van Eijk M, Aten J, Bijl N, Ottenhoff R, van Roomen CP, et al. (2009) Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation. PLoS One 4: e4723.
25. Edgerton DS, Johnson KM, Cherrington AD (2009) Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front Biosci 14: 1169-1181.
26. Lee L, Abe A, Shayman JA (1999) Improved inhibitors of glucosylceramide synthase. J Biol Chem 274: 14662-14669.
27. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, et al. (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060-1067.
28. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, et al. (2000) Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 105: 1791-1797.